NVS: Novartis AG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NVS: Novartis AG

NVS 137.94

-0.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Davy Crockett who wrote (27)	5/10/2001 4:40:22 PM
From: Starlight	Read Replies (2) of 116

Yes - This is an exciting story. The CEO of Novartis was on CNBC this afternoon. He mentioned that they are exploring treatment of other types of cancer using Gleevec, and that they are "very hopeful". It took Novartis just 2.7 years of development time to get this drug approved and on the market. It is expected to be a $0.5 billion/year drug for the company. The company has priced it comparably to existing cancer therapy drugs, and there are assistance programs for patients who cannot afford it. If I remember correctly, some patients will get the drug free (depending on their income), others will qualify for assistance (I believe yearly income ABOVE $43,000-??), and others who can afford it will pay. I don't remember the details, but no one will be denied the drug if they can't afford to pay.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next